Skip to main content

Main menu

  • Home
  • Content
    • Current
    • Ahead of print
    • Past Issues
    • JNM Supplement
    • SNMMI Annual Meeting Abstracts
    • Continuing Education
    • JNM Podcasts
  • Subscriptions
    • Subscribers
    • Institutional and Non-member
    • Rates
    • Journal Claims
    • Corporate & Special Sales
  • Authors
    • Submit to JNM
    • Information for Authors
    • Assignment of Copyright
    • AQARA requirements
  • Info
    • Reviewers
    • Permissions
    • Advertisers
  • About
    • About Us
    • Editorial Board
    • Contact Information
  • More
    • Alerts
    • Feedback
    • Help
    • SNMMI Journals
  • SNMMI
    • JNM
    • JNMT
    • SNMMI Journals
    • SNMMI

User menu

  • Subscribe
  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
Journal of Nuclear Medicine
  • SNMMI
    • JNM
    • JNMT
    • SNMMI Journals
    • SNMMI
  • Subscribe
  • My alerts
  • Log in
  • My Cart
Journal of Nuclear Medicine

Advanced Search

  • Home
  • Content
    • Current
    • Ahead of print
    • Past Issues
    • JNM Supplement
    • SNMMI Annual Meeting Abstracts
    • Continuing Education
    • JNM Podcasts
  • Subscriptions
    • Subscribers
    • Institutional and Non-member
    • Rates
    • Journal Claims
    • Corporate & Special Sales
  • Authors
    • Submit to JNM
    • Information for Authors
    • Assignment of Copyright
    • AQARA requirements
  • Info
    • Reviewers
    • Permissions
    • Advertisers
  • About
    • About Us
    • Editorial Board
    • Contact Information
  • More
    • Alerts
    • Feedback
    • Help
    • SNMMI Journals
  • View or Listen to JNM Podcast
  • Visit JNM on Facebook
  • Join JNM on LinkedIn
  • Follow JNM on Twitter
  • Subscribe to our RSS feeds
Meeting ReportIn vitro and In vivo Oncology

Preclinical evaluation of 89Zr-Df-labeled anti-VISTA antibody CI-8993

Ingrid Burvenich, Christian Wichmann, Alexander McDonald, Fiona Scott, Nancy Guo, Angela Rigopoulos, Raul Soikes, Steven Angelides, Reinhard von Roemeling and Andrew Scott
Journal of Nuclear Medicine August 2022, 63 (supplement 2) 4030;
Ingrid Burvenich
1Olivia Newton-John Cancer Research Institute
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Christian Wichmann
1Olivia Newton-John Cancer Research Institute
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Alexander McDonald
1Olivia Newton-John Cancer Research Institute
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Fiona Scott
1Olivia Newton-John Cancer Research Institute
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Nancy Guo
1Olivia Newton-John Cancer Research Institute
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Angela Rigopoulos
2Enter an organization
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Raul Soikes
3Curis Inc.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Steven Angelides
3Curis Inc.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Reinhard von Roemeling
4Curis
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Andrew Scott
5Austin Hospital
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Data
  • Info & Metrics
Loading

Article Figures & Data

Figures

  • Figure
    • Download figure
    • Open in new tab
    • Download powerpoint
Previous
Back to top

In this issue

Journal of Nuclear Medicine
Vol. 63, Issue supplement 2
August 1, 2022
  • Table of Contents
  • Index by author
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for your interest in spreading the word on Journal of Nuclear Medicine.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Preclinical evaluation of 89Zr-Df-labeled anti-VISTA antibody CI-8993
(Your Name) has sent you a message from Journal of Nuclear Medicine
(Your Name) thought you would like to see the Journal of Nuclear Medicine web site.
Citation Tools
Preclinical evaluation of 89Zr-Df-labeled anti-VISTA antibody CI-8993
Ingrid Burvenich, Christian Wichmann, Alexander McDonald, Fiona Scott, Nancy Guo, Angela Rigopoulos, Raul Soikes, Steven Angelides, Reinhard von Roemeling, Andrew Scott
Journal of Nuclear Medicine Aug 2022, 63 (supplement 2) 4030;

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
Preclinical evaluation of 89Zr-Df-labeled anti-VISTA antibody CI-8993
Ingrid Burvenich, Christian Wichmann, Alexander McDonald, Fiona Scott, Nancy Guo, Angela Rigopoulos, Raul Soikes, Steven Angelides, Reinhard von Roemeling, Andrew Scott
Journal of Nuclear Medicine Aug 2022, 63 (supplement 2) 4030;
Twitter logo Facebook logo LinkedIn logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One
Bookmark this article

Jump to section

  • Article
  • Figures & Data
  • Info & Metrics

Related Articles

  • No related articles found.
  • Google Scholar

Cited By...

  • No citing articles found.
  • Google Scholar

More in this TOC Section

  • Preliminary evaluation of 131I-labeled ITGA5 inhibitor for targeted radionuclide therapy of pancreatic cancer xenografts
  • Immuno-PET using 89Zr-labeled Glypican-1 antibody: a novel theranostic probe for the antibody-drug conjugate treatment in pancreatic cancer
  • The journey to a novel theranostic for prostate cancer : the preclinical study of 64Cu-DOTHA2-PSMA
Show more In vitro and In vivo Oncology

Similar Articles

SNMMI

© 2025 SNMMI

Powered by HighWire